Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

USA - NASDAQ:ALVO - LU2458332611 - Common Stock

8.55 USD
+0.58 (+7.28%)
Last: 10/14/2025, 3:12:24 PM
Fundamental Rating

4

Overall ALVO gets a fundamental rating of 4 out of 10. We evaluated ALVO against 536 industry peers in the Biotechnology industry. While ALVO is still in line with the averages on profitability rating, there are concerns on its financial health. ALVO is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ALVO had negative earnings in the past year.
ALVO had a negative operating cash flow in the past year.
In the past 5 years ALVO always reported negative net income.
In the past 5 years ALVO always reported negative operating cash flow.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

ALVO has a better Return On Assets (4.55%) than 91.42% of its industry peers.
The Return On Invested Capital of ALVO (3.89%) is better than 92.35% of its industry peers.
Industry RankSector Rank
ROA 4.55%
ROE N/A
ROIC 3.89%
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

ALVO has a Profit Margin of 11.26%. This is amongst the best in the industry. ALVO outperforms 92.72% of its industry peers.
Looking at the Operating Margin, with a value of 9.75%, ALVO belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.
ALVO has a Gross Margin of 53.88%. This is in the better half of the industry: ALVO outperforms 76.49% of its industry peers.
Industry RankSector Rank
OM 9.75%
PM (TTM) 11.26%
GM 53.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALVO is destroying value.
ALVO has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ALVO has an improved debt to assets ratio.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ALVO has an Altman-Z score of -0.61. This is a bad value and indicates that ALVO is not financially healthy and even has some risk of bankruptcy.
ALVO's Altman-Z score of -0.61 is in line compared to the rest of the industry. ALVO outperforms 57.28% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.61
ROIC/WACC0.56
WACC6.9%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

ALVO has a Current Ratio of 1.82. This is a normal value and indicates that ALVO is financially healthy and should not expect problems in meeting its short term obligations.
ALVO has a Current ratio of 1.82. This is in the lower half of the industry: ALVO underperforms 78.36% of its industry peers.
A Quick Ratio of 1.27 indicates that ALVO should not have too much problems paying its short term obligations.
The Quick ratio of ALVO (1.27) is worse than 83.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.27
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.39% over the past year.
ALVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 426.84%.
Measured over the past years, ALVO shows a very strong growth in Revenue. The Revenue has been growing by 42.86% on average per year.
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%

3.2 Future

ALVO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 55.64% yearly.
The Revenue is expected to grow by 44.41% on average over the next years. This is a very strong growth
EPS Next Y126.38%
EPS Next 2Y74.79%
EPS Next 3Y55.64%
EPS Next 5YN/A
Revenue Next Year44.99%
Revenue Next 2Y43.64%
Revenue Next 3Y44.41%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVO. In the last year negative earnings were reported.
ALVO is valuated reasonably with a Price/Forward Earnings ratio of 9.31.
Based on the Price/Forward Earnings ratio, ALVO is valued cheaply inside the industry as 97.95% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ALVO to the average of the S&P500 Index (22.86), we can say ALVO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.31
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

91.42% of the companies in the same industry are more expensive than ALVO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 40.66
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

ALVO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALVO's earnings are expected to grow with 55.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.79%
EPS Next 3Y55.64%

More info and screens

0

5. Dividend

5.1 Amount

ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALVOTECH SA

NASDAQ:ALVO (10/14/2025, 3:12:24 PM)

8.55

+0.58 (+7.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners5.79%
Inst Owner ChangeN/A
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap2.66B
Analysts82.22
Price Target17.85 (108.77%)
Short Float %1.25%
Short Ratio3.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)484.73%
Min EPS beat(2)411.94%
Max EPS beat(2)557.52%
EPS beat(4)4
Avg EPS beat(4)268.35%
Min EPS beat(4)38.96%
Max EPS beat(4)557.52%
EPS beat(8)5
Avg EPS beat(8)624.3%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)39.02%
Min Revenue beat(2)37.03%
Max Revenue beat(2)41.02%
Revenue beat(4)4
Avg Revenue beat(4)30.46%
Min Revenue beat(4)13.45%
Max Revenue beat(4)41.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)850%
EPS NY rev (3m)132.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.31
P/S 4.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 40.66
EPS(TTM)-0.87
EYN/A
EPS(NY)0.92
Fwd EY10.74%
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS1.81
BVpS-0.56
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.55%
ROE N/A
ROCE 4.93%
ROIC 3.89%
ROICexc 4.51%
ROICexgc 4.85%
OM 9.75%
PM (TTM) 11.26%
GM 53.88%
FCFM N/A
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 13.65
Cap/Depr 288.56%
Cap/Sales 17.29%
Interest Coverage 2.5
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.27
Altman-Z -0.61
F-Score5
WACC6.9%
ROIC/WACC0.56
Cap/Depr(3y)204.72%
Cap/Depr(5y)182.09%
Cap/Sales(3y)39.66%
Cap/Sales(5y)47.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y126.38%
EPS Next 2Y74.79%
EPS Next 3Y55.64%
EPS Next 5YN/A
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%
Revenue Next Year44.99%
Revenue Next 2Y43.64%
Revenue Next 3Y44.41%
Revenue Next 5YN/A
EBIT growth 1Y144.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year198.21%
EBIT Next 3Y93.22%
EBIT Next 5YN/A
FCF growth 1Y59.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.78%
OCF growth 3YN/A
OCF growth 5YN/A